Last reviewed · How we verify
Pazopanib use
At a glance
| Generic name | Pazopanib use |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma (PHASE2)
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (PHASE2)
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. (NA)
- Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy (PHASE4)
- Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma (PHASE1)
- Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer (PHASE1)
- Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) (PHASE1, PHASE2)
- Hepatic Monitoring for Pazopanib
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pazopanib use CI brief — competitive landscape report
- Pazopanib use updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI